261 related articles for article (PubMed ID: 20980447)
1. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
[TBL] [Abstract][Full Text] [Related]
3. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
[TBL] [Abstract][Full Text] [Related]
5. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo.
Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M
Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911
[TBL] [Abstract][Full Text] [Related]
7. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma.
Hayano K; Lee SH; Yoshida H; Zhu AX; Sahani DV
Acad Radiol; 2014 May; 21(5):654-60. PubMed ID: 24703479
[TBL] [Abstract][Full Text] [Related]
8. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
Amadori M; Barone D; Scarpi E; Oboldi D; Amadori E; Bandi G; Rossi A; Ferroni F; Ragazzini A; Casadei Gardini A; Frassineti GL; Gavelli G; Passardi A
Eur Radiol; 2018 Jul; 28(7):2969-2978. PubMed ID: 29417252
[TBL] [Abstract][Full Text] [Related]
10. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
Thukral A; Thomasson DM; Chow CK; Eulate R; Wedam SB; Gupta SN; Wise BJ; Steinberg SM; Liewehr DJ; Choyke PL; Swain SM
Radiology; 2007 Sep; 244(3):727-35. PubMed ID: 17709827
[TBL] [Abstract][Full Text] [Related]
12. Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy.
Chen BB; Hsu CY; Yu CW; Liang PC; Hsu C; Hsu CH; Cheng AL; Shih TT
Radiology; 2016 Nov; 281(2):454-464. PubMed ID: 27171020
[TBL] [Abstract][Full Text] [Related]
13. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
15. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.
Siegel AB; Cohen EI; Ocean A; Lehrer D; Goldenberg A; Knox JJ; Chen H; Clark-Garvey S; Weinberg A; Mandeli J; Christos P; Mazumdar M; Popa E; Brown RS; Rafii S; Schwartz JD
J Clin Oncol; 2008 Jun; 26(18):2992-8. PubMed ID: 18565886
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study.
Wang J; Chen LT; Tsang YM; Liu TW; Shih TT
AJR Am J Roentgenol; 2004 Sep; 183(3):713-9. PubMed ID: 15333360
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Hsu CY; Shen YC; Yu CW; Hsu C; Hu FC; Hsu CH; Chen BB; Wei SY; Cheng AL; Shih TT
J Hepatol; 2011 Oct; 55(4):858-65. PubMed ID: 21338641
[TBL] [Abstract][Full Text] [Related]
19. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
[TBL] [Abstract][Full Text] [Related]
20. Noninvasive contrast-enhanced US quantitative assessment of tumor microcirculation in a murine model: effect of discontinuing anti-VEGF therapy.
Guibal A; Taillade L; Mulé S; Comperat E; Badachi Y; Golmard JL; Le Guillou-Buffello D; Rixe O; Bridal SL; Lucidarme O
Radiology; 2010 Feb; 254(2):420-9. PubMed ID: 20093514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
